Department of Medical Microbiology, University Medical Center Utrecht (UMCU), 3584 CX Utrecht, The Netherlands.
Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht (UMCU), 3584 CX Utrecht, The Netherlands.
Viruses. 2022 Sep 17;14(9):2069. doi: 10.3390/v14092069.
Allo-HSCT with CCR5Δ32/Δ32 donor cells is the only curative HIV-1 intervention. We investigated the impact of allo-HSCT on the viral reservoir in PBMCs and post-mortem tissue in two patients. IciS-05 and IciS-11 both received a CCR5Δ32/Δ32 allo-HSCT. Before allo-HSCT, ultrasensitive HIV-1 RNA quantification; HIV-1-DNA quantification; co-receptor tropism analysis; deep-sequencing and viral characterization in PBMCs and bone marrow; and post-allo-HSCT, ultrasensitive RNA and HIV-1-DNA quantification were performed. Proviral quantification, deep sequencing, and viral characterization were done in post-mortem tissue samples. Both patients harbored subtype B CCR5-tropic HIV-1 as determined genotypically and functionally by virus culture. Pre-allo-HSCT, HIV-1-DNA could be detected in both patients in bone marrow, PBMCs, and T-cell subsets. Chimerism correlated with detectable HIV-1-DNA LTR copies in cells and tissues. Post-mortem analysis of IciS-05 revealed proviral DNA in all tissue biopsies, but not in PBMCs. In patient IciS-11, who was transplanted twice, no HIV-1-DNA could be detected in PBMCs at the time of death, whereas HIV-1-DNA was detectable in the lymph node. In conclusion, shortly after CCR5Δ32/Δ32, allo-HSCT HIV-1-DNA became undetectable in PBMCs. However, HIV-1-DNA variants identical to those present before transplantation persisted in post-mortem-obtained tissues, indicating that these tissues play an important role as viral reservoirs.
异基因造血干细胞移植(allo-HSCT)伴 CCR5Δ32/Δ32 供体细胞是唯一可治愈 HIV-1 的干预措施。我们在两名患者中研究了 allo-HSCT 对 PBMC 和尸检组织中病毒库的影响。IciS-05 和 IciS-11 均接受了 CCR5Δ32/Δ32 异基因造血干细胞移植。在 allo-HSCT 之前,进行了超灵敏 HIV-1 RNA 定量;HIV-1-DNA 定量;共受体嗜性分析;在 PBMC 和骨髓中进行深度测序和病毒特征分析;以及 allo-HSCT 后,进行超灵敏 RNA 和 HIV-1-DNA 定量。在尸检组织样本中进行了前病毒定量、深度测序和病毒特征分析。两名患者均携带 B 亚型 CCR5 嗜性 HIV-1,这是通过病毒培养从基因和功能上确定的。在 allo-HSCT 之前,两名患者的骨髓、PBMC 和 T 细胞亚群中均能检测到 HIV-1-DNA。嵌合与细胞和组织中可检测到的 HIV-1-DNA LTR 拷贝数相关。对 IciS-05 的尸检分析显示,所有组织活检均存在前病毒 DNA,但 PBMC 中不存在。在接受两次移植的患者 IciS-11 中,死亡时 PBMC 中无法检测到 HIV-1-DNA,而淋巴结中可检测到 HIV-1-DNA。总之,在接受 CCR5Δ32/Δ32 异基因造血干细胞移植后不久,PBMC 中的 HIV-1-DNA 就无法检测到。然而,移植前存在的 HIV-1-DNA 变异体在尸检获得的组织中持续存在,表明这些组织作为病毒库发挥着重要作用。